Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Research

Background:

• Autophagy inhibitors are investigated for pancreatic ductal adenocarcinoma (PDA) treatment.
• Understanding resistance mechanisms to autophagy inhibitors is crucial for clinical efficacy.

Purpose of the Study:

• To uncover metabolic adaptations that bypass autophagy inhibition in PDA.
• To identify vulnerabilities associated with acquired resistance to autophagy inhibitors.

Main Methods:

• Utilized PDA cells with acquired resistance to various autophagy inhibitors.
• Analyzed metabolic rewiring, focusing on TCA intermediates, nucleotides, and pyruvate metabolism.
• Investigated pyrimidine salvage pathways versus de novo synthesis.

Main Results:

• Severe autophagy depletion induces metabolic rewiring to sustain biosynthesis.
• Long-term autophagy inhibition alters pyruvate metabolism, linked to reduced pyrimidine pools.
• Resistant cells preferentially salvage pyrimidines, increasing sensitivity to pyrimidine analogs.

Conclusions:

• Acquired resistance to autophagy inhibition creates a metabolic vulnerability to pyrimidine analogs.
• Combining autophagy inhibitors with pyrimidine analogs (gemcitabine, trifluridine/tipiracil) shows synergistic effects.
• This research provides insights into leveraging autophagy inhibition for pancreatic cancer therapy.